高剂量与低剂量氨甲环酸输注对心脏手术患者红细胞输注需求及不良事件的影响:OPTIMAL随机临床试验
这项多中心、双盲、随机临床试验在中国4家医院纳入3079例体外循环心脏手术成人患者,比较高剂量与低剂量氨甲环酸方案。高剂量组同种异体红细胞输注率为21.8%,低剂量组为26.0%(风险差-4.1%,单侧97.55%CI -∞至-1.1%;相对风险0.84,单侧97.55%CI -∞至0.96;P=0.004)。主要安全终点复合指标高剂量组17.6%、低剂量组16.8%(风险差0.8%,单侧97.55%CI -∞至3.9%;非劣效P=0.003)。
要点
- 高剂量较低剂量氨甲环酸降低体外循环心脏手术患者红细胞输注率(21.8% vs 26.0%)。
- 主要安全复合终点(30天死亡、癫痫发作、肾功能障碍、血栓事件)高剂量组非劣效于低剂量组。
- 癫痫发作高剂量组1.0% vs 低剂量组0.4%(风险差0.6%,95%CI -0.0%至1.2%;P=0.05)。
核心结论
- 在体外循环心脏手术患者中,高剂量较低剂量氨甲环酸输注使接受同种异体红细胞输注的患者比例出现幅度不大但具有统计学意义的降低,且主要安全复合终点达到非劣效。
研究设计与样本
- 多中心、双盲、随机临床试验,纳入中国4家医院3079例体外循环心脏手术成人患者,2018年12月26日至2021年4月21日入组,最终随访2021年5月21日;3031例(98.4%)完成试验。
主要发现
- 同种异体红细胞输注:高剂量组333/1525例(21.8%),低剂量组391/1506例(26.0%),风险差-4.1%(单侧97.55%CI -∞至-1.1%),相对风险0.84(单侧97.55%CI -∞至0.96;P=0.004)。
- 主要安全复合终点(术后30天死亡、癫痫发作、肾功能障碍[KDIGO 2或3期]、血栓事件):高剂量组265例(17.6%),低剂量组249例(16.8%),风险差0.8%(单侧97.55%CI -∞至3.9%),非劣效P=0.003。
- 15个预设次要终点中14个组间无显著差异;癫痫发作高剂量组15例(1.0%),低剂量组6例(0.4%),风险差0.6%(95%CI -0.0%至1.2%;P=0.05)。
关键数值与推荐
- 高剂量方案:30 mg/kg负荷量、16 mg/kg/h维持量、2 mg/kg预充量(n=1525)。
- 低剂量方案:10 mg/kg负荷量、2 mg/kg/h维持量、1 mg/kg预充量(n=1506)。
- 主要安全终点非劣效界值为5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Tranexamic acid is recommended for reducing blood loss and transfusion in cardiac surgery. However, it remains unknown whether a high dose of tranexamic acid provides better blood-sparing effect than a low dose without increasing the risk of thrombotic complications or seizures in cardiac surgery. OBJECTIVE: To compare the efficacy and adverse events of high-dose vs low-dose tranexamic acid in patients undergoing cardiac surgery with cardiopulmonary bypass. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, double-blind, randomized clinical trial among adult patients undergoing cardiac surgery with cardiopulmonary bypass. The study enrolled 3079 patients at 4 hospitals in China from December 26, 2018, to April 21, 2021; final follow-up was on May 21, 2021. INTERVENTIONS: Participants received either a high-dose tranexamic acid regimen comprising a 30-mg/kg bolus, a 16-mg/kg/h maintenance dose, and a 2-mg/kg prime (n = 1525) or a low-dose regimen comprising a 10-mg/kg bolus, a 2-mg/kg/h maintenance dose, and a 1-mg/kg prime (n = 1506). MAIN OUTCOMES AND MEASURES: The primary efficacy end point was the rate of allogeneic red blood cell transfusion after start of operation (superiority hypothesis), and the primary safety end point was a composite of the 30-day postoperative rate of mortality, seizure, kidney dysfunction (stage 2 or 3 Kidney Disease: Improving Global Outcomes [KDIGO] criteria), and thrombotic events (myocardial infarction, ischemic stroke, deep vein thrombosis, and pulmonary embolism) (noninferiority hypothesis with a margin of 5%). There were 15 secondary end points, including the individual components of the primary safety end point. RESULTS: Among 3079 patients who were randomized to treatment groups (mean age, 52.8 years; 38.1% women), 3031 (98.4%) completed the trial. Allogeneic red blood cell transfusion occurred in 333 of 1525 patients (21.8%) in the high-dose group and 391 of 1506 patients (26.0%) in the low-dose group (risk difference [RD], -4.1% [1-sided 97.55% CI, -∞ to -1.1%]; relative risk, 0.84 [1-sided 97.55% CI, -∞ to 0.96; P = .004]). The composite of postoperative seizure, thrombotic events, kidney dysfunction, and death occurred in 265 patients in the high-dose group (17.6%) and 249 patients in the low-dose group (16.8%) (RD, 0.8%; 1-sided 97.55% CI, -∞ to 3.9%; P = .003 for noninferiority). Fourteen of the 15 prespecified secondary end points were not significantly different between groups, including seizure, which occurred in 15 patients (1.0%) in the high-dose group and 6 patients (0.4%) in the low-dose group (RD, 0.6%; 95% CI, -0.0% to 1.2%; P = .05). CONCLUSIONS AND RELEVANCE: Among patients who underwent cardiac surgery with cardiopulmonary bypass, high-dose compared with low-dose tranexamic acid infusion resulted in a modest statistically significant reduction in the proportion of patients who received allogeneic red blood cell transfusion and met criteria for noninferiority with respect to a composite primary safety end point consisting of 30-day mortality, seizure, kidney dysfunction, and thrombotic events. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03782350.
引用
- Shi J, Zhou C, Pan W, et al. Effect of High- vs Low-Dose Tranexamic Acid Infusion on Need for Red Blood Cell Transfusion and Adverse Events in Patients Undergoing Cardiac Surgery: The OPTIMAL Randomized Clinical Trial. JAMA. 2022. PMID: 35881121. doi:10.1001/jama.2022.10725
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。